Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Champions Oncolog (CSBR)

Champions Oncolog (CSBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,851
  • Shares Outstanding, K 13,827
  • Annual Sales, $ 50,160 K
  • Annual Income, $ -7,280 K
  • EBIT $ 7 M
  • EBITDA $ 9 M
  • 60-Month Beta 0.44
  • Price/Sales 1.86
  • Price/Cash Flow N/A
  • Price/Book 20.14

Options Overview Details

View History
  • Implied Volatility 282.01% ( +22.86%)
  • Historical Volatility 91.34%
  • IV Percentile 84%
  • IV Rank 57.64%
  • IV High 482.03% on 12/02/24
  • IV Low 9.88% on 07/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 471
  • Open Int (30-Day) 469

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +525,889.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.98 +11.89%
on 06/26/25
9.63 -18.90%
on 07/09/25
+0.20 (+2.63%)
since 06/16/25
3-Month
5.59 +39.66%
on 05/27/25
9.63 -18.90%
on 07/09/25
-0.50 (-6.02%)
since 04/16/25
52-Week
3.60 +116.94%
on 09/10/24
11.99 -34.86%
on 01/28/25
+2.95 (+60.70%)
since 07/16/24

Most Recent Stories

More News
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical...

CSBR : 7.80 (unch)
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of the...

CSBR : 7.80 (unch)
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...

CSBR : 7.80 (unch)
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025

HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report...

CSBR : 7.80 (unch)
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance...

CSBR : 7.80 (unch)
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce...

CSBR : 7.80 (unch)
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced...

CSBR : 7.80 (unch)
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report...

CSBR : 7.80 (unch)
Champions Oncology Announces Agreement with Weill Cornell Medicine

HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement...

CSBR : 7.80 (unch)
Stocks Rise Before the Open as Investors Await Key U.S. PPI Data, ECB Decision in Focus

September S&P 500 E-Mini futures (ESU24) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.27% this morning as investors braced for crucial U.S. producer inflation data while also...

ENPH : 39.03 (-3.03%)
NVDA : 171.36 (+0.38%)
ROG.Z.IX : 255.900 (+0.67%)
IPG : 25.20 (+4.18%)
NQU24 : 19,808.01s (-0.21%)
OXM : 42.85 (-1.06%)
MU : 116.43 (-3.06%)
FSLR : 166.82 (-2.97%)
PCH : 40.79 (+2.38%)
ALB : 70.41 (+0.56%)
ADBE : 361.77 (-0.66%)
ESU24 : 5,699.99s (-0.31%)

Business Summary

Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the...

See More

Key Turning Points

3rd Resistance Point 8.98
2nd Resistance Point 8.66
1st Resistance Point 8.23
Last Price 7.80
1st Support Level 7.48
2nd Support Level 7.16
3rd Support Level 6.73

See More

52-Week High 11.99
Fibonacci 61.8% 8.79
Fibonacci 50% 7.80
Last Price 7.80
Fibonacci 38.2% 6.81
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar